University of Minnesota Health Cancer Care is known for its innovative and groundbreaking care for patients with blood cancers. Many treatments that are now available to patients around the world were pioneered at our National Cancer Institute-designated Comprehensive Cancer Center: Masonic Cancer Center, University of Minnesota.
We have been a world leader in treating hematologic malignancies with blood and marrow transplant (BMT) since 1968, when the world’s first successful BMT for a cancer patient was performed here. Since then, our physicians have performed roughly 6,000 transplants for patients with leukemia, lymphoma, myeloma and other blood cancers.
More detailed information about specific blood cancers can be found by clicking on the links below.
- Cutaneous T-Cell Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome and Myeloproliferative Diseases
Our care team creates individualized treatment plans for patients with cancers of the blood by evaluating not only the type and severity of the disease, but also the patient’s overall health and goals for treatment.
We continue to perform leading-edge research, including the use of cellular therapy to motivate the body’s own “natural killer” cells to destroy cancer cells. This research, conducted in collaboration with scientists at the Masonic Cancer Center, benefits patients who have not responded to standard therapies.